Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on June 7, 2016. The filing details the entry into a new senior secured loan facility and the termination of a prior material definitive agreement.
Key Financial Metrics and Transaction Details
- Loan Facility: A senior secured loan facility with an aggregate principal amount of up to $70 million.
- Initial Draw: $55 million drawn on June 7, 2016.
- Interest Rate (Initial): 8.25% annual interest rate.
- Optional Draw: Up to $15 million available during the second calendar quarter of 2017 at the prime rate plus 4.75%.
- Use of Proceeds: Refinancing of the current outstanding term loan, payment of associated final payment fees, working capital, and general business requirements.
- Repayment Terms: Interest-only payments for the first 18 months, followed by equal monthly principal and interest payments through the maturity date of January 1, 2021.
- Final Payment Fee: 5.50% of the initial $55 million principal; 7.25% of the principal if the additional $15 million is drawn.
- Collateral: Substantially all assets of the Borrowers, excluding equity interest in Halozyme, Inc., intellectual property, and certain other excluded assets.
Material Changes Versus Prior Period
On June 7, 2016, the Company terminated its Amended and Restated Loan and Security Agreement dated December 23, 2013, and all subsequent amendments. This termination was executed in connection with the entry into the new Loan Agreement with Oxford Finance LLC and Silicon Valley Bank.
Outlook, Risks, and Management Commentary
The filing indicates the Company intends to file the full text of the Loan Agreement as an exhibit to its Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2016. The agreement contains customary representations, warranties, covenants, events of default, and indemnification obligations. The filing does not provide specific forward-looking guidance on revenue or profit margins, as the document focuses on the financing transaction.
Key Facts for Investor Verification
- Verify the impact of the 8.25% interest rate and the 5.50% final payment fee on future cash flow projections.
- Confirm the specific covenants and events of default detailed in the full Loan Agreement (to be filed in the 10-Q).
- Monitor the Company's decision regarding the optional $15 million draw in Q2 2017 and the associated higher fee structure (7.25%).
- Review the exclusion of intellectual property from the collateral package to understand the security position of the lenders.